ReviewMagyar onkologia2026
[The role of sentinel lymph node biopsy in the management of gynecologic cancers: current evidence and institutional experience].
Review in Magyar onkologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo critically review the current role of sentinel lymph node (SLN) biopsy in endometrial, cervical, vulvar and ovarian cancer, and to compare international evidence with a single institution's surgical experience.
methodsTargeted appraisal of randomized trials, prospective cohorts, systematic reviews and meta-analyses, complemented by retrospective, descriptive institutional data on 141 patients (indocyanine green mapping; robotic and laparoscopic platforms).
resultsIn endometrial cancer, available prospective and meta-analytic data indicate that SLN biopsy is not associated with worse oncologic outcomes than systematic lymphadenectomy. In early cervical cancer, a recent randomized trial showed that SLN biopsy alone is non-inferior to lymphadenectomy while reducing surgical morbidity. In appropriately selected vulvar cancer, groin de-escalation provides the clearest morbidity benefit. In ovarian cancer, the technique remains investigational. The institutional bilateral detection rate (78.7%) was consistent with contemporary international data.
conclusionsSLN biopsy is a key surgical de-escalation strategy in gynecologic oncology which, with adequate pathological ultrastaging, also improves oncologic staging accuracy; its success depends on patient selection and centre experience.
Indexed as
Identifiers
42731005PMC13577715What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.